SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Nishihori Taiga)) pers:(Gale Robert Peter)
 

Sökning: (WFRF:(Nishihori Taiga)) pers:(Gale Robert Peter) > Outcomes after Umbi...

  • Gerds, Aaron T.Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA. (författare)

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • Elsevier,2017
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-327230
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327230URI
  • https://doi.org/10.1016/j.bbmt.2017.03.014DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135969058URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor. To date, however, there have been few published series dedicated solely to describing the outcomes of adult patients with myelodysplastic syndrome (MDS) who have undergone UCBT. Between 2004 and 2013, 176 adults with MDS underwent UCBT as reported to the Center for International Blood and Marrow Transplant Research. Median age at the time of transplantation was 56 years (range, 18-73 years). The study group included 10% with very low, 23% with low, 19% with intermediate, 19% with high, and 13% with very high-risk Revised International Prognostic Scoring System (IPSS-R) scores. The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%, and the 3-year probability of chronic GVHD was 28%. The probabilities of relapse and transplantation-related mortality (TRM) at 3 years were 32% and 40%, respectively, leading to a 3-year disease-free survival (DFS) of 28% and an overall survival (OS) of 31%. In multivariate analysis, increasing IPSS-R score at the time of HCT was associated with inferior TRM (P = .0056), DFS (P = .018), and OS (P = .0082), but not with GVHD or relapse. The presence of pretransplantation comorbidities was associated with TRM (P = .001), DFS (P = .02), and OS (P = .001). Reduced intensity conditioning was associated with increased risk of relapse (relative risk, 3.95; 95% confidence interval, 1.78-8.75; P < .001), and although a higher proportion of myeloablative UCBTs were performed in patients with high-risk disease, the effect of conditioning regimen intensity was the same regardless of IPSS-R score. For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in this population is hampered by a high rate of TRM. (C) 2017 American Society for Blood and Marrow Transplantation.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Ahn, Kwang WooMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (författare)
  • Hu, Zhen-HuanMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (författare)
  • Abdel-Azim, HishamUniv Southern Calif, Keck Sch Med, Childrens Hosp Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA. (författare)
  • Akpek, GorgunRush Univ, Med Ctr, Dept Internal Med, Stem Cell Transplantat & Cell Therapy, Chicago, IL 60612 USA. (författare)
  • Aljurf, MahmoudKing Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia. (författare)
  • Ballen, Karen K.Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. (författare)
  • Beitinjaneh, AmerUniv Miami, Div Hematol & Oncol, Miami, FL USA. (författare)
  • Bacher, UlrikeInselspital Bern, Dept Hematol, Bern, Switzerland.;Univ Canc Ctr Hamburg, Interdisciplinary Clin Stem Cell Transplantat, Hamburg, Germany. (författare)
  • Cahn, Jean-YvesUniv Hosp, Dept Hematol, Grenoble, France. (författare)
  • Chhabra, SaurabhMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (författare)
  • Cutler, CoreyDana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA. (författare)
  • Daly, AndrewTom Baker Canc Clin, Calgary, AB, Canada. (författare)
  • DeFilipp, ZachariahMassachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. (författare)
  • Gale, Robert PeterImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. (författare)
  • Gergis, UsamaNew York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Med Oncol, Hematolg Malignancies & Bone Marrow Transplant, New York, NY USA. (författare)
  • Grunwald, Michael R.Levine Canc Inst, Charlotte, NC USA. (författare)
  • Hale, Gregory A.Johns Hopkins All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL USA. (författare)
  • Hamilton, Betty KyCleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. (författare)
  • Jagasia, MadanVanderbilt Univ, Med Ctr, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA. (författare)
  • Kamble, Rammurti T.Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA. (författare)
  • Kindwall-Keller, TamilaUniv Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA. (författare)
  • Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (författare)
  • Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.(Swepub:uu)riols677 (författare)
  • Ramanathan, MuthalaguUMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA. (författare)
  • Saad, Ayman A.Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. (författare)
  • Solh, MelhemNorthside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA. (författare)
  • Ustun, CelalettinUniv Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. (författare)
  • Valcarcel, DavidHosp Valle De Hebron, Dept Hematol, Barcelona, Spain. (författare)
  • Warlick, EricaUniv Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. (författare)
  • Wirk, Baldeep M.Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA. (författare)
  • Kalaycio, MattCleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA. (författare)
  • Alyea, EdwinDana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA. (författare)
  • Popat, UdayMD Anderson Canc Ctr, Houston, TX USA. (författare)
  • Sobecks, RonaldCleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA. (författare)
  • Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (författare)
  • Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA.Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Biology of blood and marrow transplantation: Elsevier23:6, s. 971-9791083-87911523-6536

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy